nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—UGT1A1—Etoposide—muscle cancer	0.114	0.136	CbGbCtD
Lovastatin—ABCC2—Vincristine—muscle cancer	0.0756	0.0905	CbGbCtD
Lovastatin—ABCC2—Etoposide—muscle cancer	0.0692	0.0829	CbGbCtD
Lovastatin—SLCO1A2—Methotrexate—muscle cancer	0.0552	0.0661	CbGbCtD
Lovastatin—SLCO1B1—Methotrexate—muscle cancer	0.0521	0.0623	CbGbCtD
Lovastatin—CYP3A7—Vincristine—muscle cancer	0.0504	0.0604	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0504	0.0604	CbGbCtD
Lovastatin—ABCC2—Doxorubicin—muscle cancer	0.0472	0.0566	CbGbCtD
Lovastatin—ABCC2—Methotrexate—muscle cancer	0.0457	0.0548	CbGbCtD
Lovastatin—ABCB1—Dactinomycin—muscle cancer	0.04	0.0479	CbGbCtD
Lovastatin—CYP3A5—Vincristine—muscle cancer	0.0378	0.0453	CbGbCtD
Lovastatin—CYP3A5—Etoposide—muscle cancer	0.0347	0.0415	CbGbCtD
Lovastatin—CYP2C8—Etoposide—muscle cancer	0.0333	0.0399	CbGbCtD
Lovastatin—ABCB1—Vincristine—muscle cancer	0.0246	0.0295	CbGbCtD
Lovastatin—ABCB1—Etoposide—muscle cancer	0.0226	0.027	CbGbCtD
Lovastatin—ABCB1—Doxorubicin—muscle cancer	0.0154	0.0184	CbGbCtD
Lovastatin—ABCB1—Methotrexate—muscle cancer	0.0149	0.0179	CbGbCtD
Lovastatin—CYP3A4—Vincristine—muscle cancer	0.0148	0.0177	CbGbCtD
Lovastatin—CYP2D6—Doxorubicin—muscle cancer	0.0145	0.0174	CbGbCtD
Lovastatin—CYP3A4—Etoposide—muscle cancer	0.0135	0.0162	CbGbCtD
Lovastatin—CYP3A4—Doxorubicin—muscle cancer	0.00922	0.011	CbGbCtD
Lovastatin—HDAC2—Teniposide—Etoposide—muscle cancer	0.00438	1	CbGdCrCtD
Lovastatin—ITGAL—tendon—muscle cancer	0.00299	0.0501	CbGeAlD
Lovastatin—PON3—tendon—muscle cancer	0.00294	0.0491	CbGeAlD
Lovastatin—ITGAL—bone marrow—muscle cancer	0.0029	0.0485	CbGeAlD
Lovastatin—VIIth nerve paralysis—Vincristine—muscle cancer	0.00285	0.0341	CcSEcCtD
Lovastatin—PON3—bone marrow—muscle cancer	0.00284	0.0476	CbGeAlD
Lovastatin—ITGAL—vagina—muscle cancer	0.00278	0.0465	CbGeAlD
Lovastatin—PON3—vagina—muscle cancer	0.00272	0.0456	CbGeAlD
Lovastatin—ITGAL—testis—muscle cancer	0.00248	0.0415	CbGeAlD
Lovastatin—PON3—testis—muscle cancer	0.00243	0.0407	CbGeAlD
Lovastatin—Cognitive impairment—Methotrexate—muscle cancer	0.00217	0.026	CcSEcCtD
Lovastatin—HDAC2—embryo—muscle cancer	0.00202	0.0339	CbGeAlD
Lovastatin—Nodule—Methotrexate—muscle cancer	0.00193	0.0231	CcSEcCtD
Lovastatin—UGT2B7—renal system—muscle cancer	0.00187	0.0313	CbGeAlD
Lovastatin—UGT1A1—renal system—muscle cancer	0.00159	0.0266	CbGeAlD
Lovastatin—HDAC2—smooth muscle tissue—muscle cancer	0.00159	0.0266	CbGeAlD
Lovastatin—HDAC2—renal system—muscle cancer	0.00153	0.0256	CbGeAlD
Lovastatin—HMGCR—smooth muscle tissue—muscle cancer	0.00144	0.024	CbGeAlD
Lovastatin—HMGCR—renal system—muscle cancer	0.00138	0.0231	CbGeAlD
Lovastatin—SLCO1B1—renal system—muscle cancer	0.00132	0.0222	CbGeAlD
Lovastatin—Cognitive disorder—Methotrexate—muscle cancer	0.00131	0.0157	CcSEcCtD
Lovastatin—ITGAL—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD34—muscle cancer	0.00128	0.0744	CbGpPWpGaD
Lovastatin—HMGCR—cardiac atrium—muscle cancer	0.00124	0.0207	CbGeAlD
Lovastatin—Loss of libido—Methotrexate—muscle cancer	0.00123	0.0147	CcSEcCtD
Lovastatin—UGT2B7—testis—muscle cancer	0.00121	0.0203	CbGeAlD
Lovastatin—HDAC2—tendon—muscle cancer	0.0012	0.02	CbGeAlD
Lovastatin—Musculoskeletal pain—Vincristine—muscle cancer	0.00118	0.0141	CcSEcCtD
Lovastatin—HDAC2—bone marrow—muscle cancer	0.00116	0.0194	CbGeAlD
Lovastatin—HDAC2—vagina—muscle cancer	0.00111	0.0186	CbGeAlD
Lovastatin—ITGAL—Cell surface interactions at the vascular wall—ANGPT2—muscle cancer	0.00109	0.0632	CbGpPWpGaD
Lovastatin—HMGCR—tendon—muscle cancer	0.00108	0.0181	CbGeAlD
Lovastatin—SLCO1A2—renal system—muscle cancer	0.00108	0.018	CbGeAlD
Lovastatin—Hepatic failure—Dactinomycin—muscle cancer	0.00106	0.0126	CcSEcCtD
Lovastatin—HMGCR—bone marrow—muscle cancer	0.00105	0.0175	CbGeAlD
Lovastatin—HDAC2—head—muscle cancer	0.00103	0.0172	CbGeAlD
Lovastatin—ABCC2—renal system—muscle cancer	0.001	0.0168	CbGeAlD
Lovastatin—HMGCR—vagina—muscle cancer	0.001	0.0168	CbGeAlD
Lovastatin—HDAC2—testis—muscle cancer	0.000991	0.0166	CbGeAlD
Lovastatin—Phosphatase alkaline increased—Etoposide—muscle cancer	0.000947	0.0113	CcSEcCtD
Lovastatin—Hepatic failure—Vincristine—muscle cancer	0.000944	0.0113	CcSEcCtD
Lovastatin—HMGCR—head—muscle cancer	0.000925	0.0155	CbGeAlD
Lovastatin—HMGCR—testis—muscle cancer	0.000894	0.015	CbGeAlD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.000889	0.0516	CbGpPWpGaD
Lovastatin—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.000855	0.0102	CcSEcCtD
Lovastatin—Pain in extremity—Vincristine—muscle cancer	0.000849	0.0101	CcSEcCtD
Lovastatin—Transaminases increased—Doxorubicin—muscle cancer	0.000807	0.00965	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.00079	0.00945	CcSEcCtD
Lovastatin—ABCC2—tendon—muscle cancer	0.000784	0.0131	CbGeAlD
Lovastatin—CYP2C8—renal system—muscle cancer	0.000753	0.0126	CbGeAlD
Lovastatin—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.000726	0.00868	CcSEcCtD
Lovastatin—SLCO1A2—head—muscle cancer	0.000721	0.0121	CbGeAlD
Lovastatin—SLCO1A2—testis—muscle cancer	0.000697	0.0117	CbGeAlD
Lovastatin—CYP3A5—renal system—muscle cancer	0.00068	0.0114	CbGeAlD
Lovastatin—Erectile dysfunction—Vincristine—muscle cancer	0.000675	0.00808	CcSEcCtD
Lovastatin—Photosensitivity reaction—Vincristine—muscle cancer	0.000669	0.00801	CcSEcCtD
Lovastatin—Hepatitis—Dactinomycin—muscle cancer	0.000657	0.00786	CcSEcCtD
Lovastatin—ABCC2—testis—muscle cancer	0.000649	0.0109	CbGeAlD
Lovastatin—Neuropathy peripheral—Vincristine—muscle cancer	0.000641	0.00767	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.000636	0.0369	CbGpPWpGaD
Lovastatin—HDAC2—Neural Crest Differentiation—PAX7—muscle cancer	0.000627	0.0364	CbGpPWpGaD
Lovastatin—CYP2C19—vagina—muscle cancer	0.000625	0.0105	CbGeAlD
Lovastatin—Erythema multiforme—Dactinomycin—muscle cancer	0.000621	0.00743	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.000619	0.0074	CcSEcCtD
Lovastatin—Cramp muscle—Etoposide—muscle cancer	0.000619	0.0074	CcSEcCtD
Lovastatin—Flushing—Dactinomycin—muscle cancer	0.00061	0.00729	CcSEcCtD
Lovastatin—Chills—Dactinomycin—muscle cancer	0.00059	0.00705	CcSEcCtD
Lovastatin—Vasculitis—Methotrexate—muscle cancer	0.000581	0.00695	CcSEcCtD
Lovastatin—Alopecia—Dactinomycin—muscle cancer	0.000581	0.00694	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.000573	0.0332	CbGpPWpGaD
Lovastatin—Jaundice cholestatic—Doxorubicin—muscle cancer	0.000559	0.00668	CcSEcCtD
Lovastatin—CYP2C8—vagina—muscle cancer	0.000546	0.00913	CbGeAlD
Lovastatin—HDAC2—Neural Crest Differentiation—PAX3—muscle cancer	0.000533	0.031	CbGpPWpGaD
Lovastatin—Ill-defined disorder—Dactinomycin—muscle cancer	0.000531	0.00635	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000525	0.00628	CcSEcCtD
Lovastatin—Neuropathy peripheral—Etoposide—muscle cancer	0.000519	0.00621	CcSEcCtD
Lovastatin—Alopecia—Vincristine—muscle cancer	0.000519	0.0062	CcSEcCtD
Lovastatin—Malaise—Dactinomycin—muscle cancer	0.000516	0.00617	CcSEcCtD
Lovastatin—Leukopenia—Dactinomycin—muscle cancer	0.000512	0.00612	CcSEcCtD
Lovastatin—ITGAL—Extracellular matrix organization—DMD—muscle cancer	0.000511	0.0297	CbGpPWpGaD
Lovastatin—CYP3A4—renal system—muscle cancer	0.00051	0.00854	CbGeAlD
Lovastatin—Gynaecomastia—Methotrexate—muscle cancer	0.000507	0.00607	CcSEcCtD
Lovastatin—CYP2D6—renal system—muscle cancer	0.000502	0.0084	CbGeAlD
Lovastatin—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000497	0.00594	CcSEcCtD
Lovastatin—Back pain—Vincristine—muscle cancer	0.000494	0.00591	CcSEcCtD
Lovastatin—CYP3A5—vagina—muscle cancer	0.000492	0.00824	CbGeAlD
Lovastatin—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.000491	0.00587	CcSEcCtD
Lovastatin—Myalgia—Dactinomycin—muscle cancer	0.000487	0.00582	CcSEcCtD
Lovastatin—CYP2C8—testis—muscle cancer	0.000487	0.00815	CbGeAlD
Lovastatin—Discomfort—Dactinomycin—muscle cancer	0.000481	0.00575	CcSEcCtD
Lovastatin—ABCB1—embryo—muscle cancer	0.000477	0.00799	CbGeAlD
Lovastatin—Photosensitivity—Methotrexate—muscle cancer	0.000469	0.00561	CcSEcCtD
Lovastatin—Infection—Dactinomycin—muscle cancer	0.000464	0.00555	CcSEcCtD
Lovastatin—Vertigo—Vincristine—muscle cancer	0.000459	0.00549	CcSEcCtD
Lovastatin—Hepatic failure—Methotrexate—muscle cancer	0.000458	0.00548	CcSEcCtD
Lovastatin—Leukopenia—Vincristine—muscle cancer	0.000457	0.00547	CcSEcCtD
Lovastatin—Thrombocytopenia—Dactinomycin—muscle cancer	0.000457	0.00547	CcSEcCtD
Lovastatin—Erythema multiforme—Etoposide—muscle cancer	0.00045	0.00538	CcSEcCtD
Lovastatin—Anorexia—Dactinomycin—muscle cancer	0.000445	0.00532	CcSEcCtD
Lovastatin—Flushing—Etoposide—muscle cancer	0.000441	0.00528	CcSEcCtD
Lovastatin—Myalgia—Vincristine—muscle cancer	0.000435	0.0052	CcSEcCtD
Lovastatin—Chills—Etoposide—muscle cancer	0.000427	0.0051	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000425	0.00509	CcSEcCtD
Lovastatin—HDAC2—Hedgehog signaling events mediated by Gli proteins—PTCH1—muscle cancer	0.000421	0.0244	CbGpPWpGaD
Lovastatin—Alopecia—Etoposide—muscle cancer	0.00042	0.00503	CcSEcCtD
Lovastatin—Anaphylactic shock—Vincristine—muscle cancer	0.000417	0.00499	CcSEcCtD
Lovastatin—Infection—Vincristine—muscle cancer	0.000414	0.00495	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00041	0.0049	CcSEcCtD
Lovastatin—Thrombocytopenia—Vincristine—muscle cancer	0.000408	0.00488	CcSEcCtD
Lovastatin—Hepatic function abnormal—Doxorubicin—muscle cancer	0.000408	0.00488	CcSEcCtD
Lovastatin—Photosensitivity—Doxorubicin—muscle cancer	0.000406	0.00486	CcSEcCtD
Lovastatin—Decreased appetite—Dactinomycin—muscle cancer	0.000406	0.00485	CcSEcCtD
Lovastatin—Dysgeusia—Etoposide—muscle cancer	0.000405	0.00485	CcSEcCtD
Lovastatin—Fatigue—Dactinomycin—muscle cancer	0.000402	0.00481	CcSEcCtD
Lovastatin—Back pain—Etoposide—muscle cancer	0.0004	0.00479	CcSEcCtD
Lovastatin—Pain—Dactinomycin—muscle cancer	0.000399	0.00477	CcSEcCtD
Lovastatin—Vascular purpura—Doxorubicin—muscle cancer	0.000399	0.00477	CcSEcCtD
Lovastatin—Muscle spasms—Etoposide—muscle cancer	0.000398	0.00476	CcSEcCtD
Lovastatin—Anorexia—Vincristine—muscle cancer	0.000398	0.00475	CcSEcCtD
Lovastatin—Hepatic failure—Doxorubicin—muscle cancer	0.000397	0.00474	CcSEcCtD
Lovastatin—Feeling abnormal—Dactinomycin—muscle cancer	0.000385	0.0046	CcSEcCtD
Lovastatin—Ill-defined disorder—Etoposide—muscle cancer	0.000384	0.00459	CcSEcCtD
Lovastatin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000382	0.00456	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00038	0.00454	CcSEcCtD
Lovastatin—Insomnia—Vincristine—muscle cancer	0.000377	0.00451	CcSEcCtD
Lovastatin—UGT1A3—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000377	0.0219	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of Telomerase—WT1—muscle cancer	0.000375	0.0217	CbGpPWpGaD
Lovastatin—Paraesthesia—Vincristine—muscle cancer	0.000374	0.00448	CcSEcCtD
Lovastatin—Malaise—Etoposide—muscle cancer	0.000373	0.00446	CcSEcCtD
Lovastatin—Vertigo—Etoposide—muscle cancer	0.000372	0.00445	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000371	0.00443	CcSEcCtD
Lovastatin—Leukopenia—Etoposide—muscle cancer	0.000371	0.00443	CcSEcCtD
Lovastatin—Purpura—Doxorubicin—muscle cancer	0.00037	0.00442	CcSEcCtD
Lovastatin—Abdominal pain—Dactinomycin—muscle cancer	0.000369	0.00441	CcSEcCtD
Lovastatin—Body temperature increased—Dactinomycin—muscle cancer	0.000369	0.00441	CcSEcCtD
Lovastatin—Decreased appetite—Vincristine—muscle cancer	0.000363	0.00434	CcSEcCtD
Lovastatin—ABCB1—renal system—muscle cancer	0.000361	0.00604	CbGeAlD
Lovastatin—Fatigue—Vincristine—muscle cancer	0.00036	0.0043	CcSEcCtD
Lovastatin—Pain—Vincristine—muscle cancer	0.000357	0.00426	CcSEcCtD
Lovastatin—Constipation—Vincristine—muscle cancer	0.000357	0.00426	CcSEcCtD
Lovastatin—Pain in extremity—Doxorubicin—muscle cancer	0.000357	0.00426	CcSEcCtD
Lovastatin—Chest pain—Etoposide—muscle cancer	0.000352	0.00421	CcSEcCtD
Lovastatin—Eosinophilia—Methotrexate—muscle cancer	0.000352	0.00421	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	0.00035	0.0203	CbGpPWpGaD
Lovastatin—Pancreatitis—Methotrexate—muscle cancer	0.000349	0.00417	CcSEcCtD
Lovastatin—Discomfort—Etoposide—muscle cancer	0.000348	0.00416	CcSEcCtD
Lovastatin—Hypersensitivity—Dactinomycin—muscle cancer	0.000344	0.00411	CcSEcCtD
Lovastatin—Abdominal discomfort—Methotrexate—muscle cancer	0.000341	0.00408	CcSEcCtD
Lovastatin—Gastrointestinal pain—Vincristine—muscle cancer	0.000341	0.00408	CcSEcCtD
Lovastatin—Confusional state—Etoposide—muscle cancer	0.000341	0.00407	CcSEcCtD
Lovastatin—Anaphylactic shock—Etoposide—muscle cancer	0.000338	0.00404	CcSEcCtD
Lovastatin—CYP2D6—head—muscle cancer	0.000336	0.00562	CbGeAlD
Lovastatin—Infection—Etoposide—muscle cancer	0.000336	0.00401	CcSEcCtD
Lovastatin—Asthenia—Dactinomycin—muscle cancer	0.000335	0.00401	CcSEcCtD
Lovastatin—Thrombocytopenia—Etoposide—muscle cancer	0.000331	0.00396	CcSEcCtD
Lovastatin—Body temperature increased—Vincristine—muscle cancer	0.00033	0.00394	CcSEcCtD
Lovastatin—Abdominal pain—Vincristine—muscle cancer	0.00033	0.00394	CcSEcCtD
Lovastatin—Erectile dysfunction—Methotrexate—muscle cancer	0.000328	0.00392	CcSEcCtD
Lovastatin—Photosensitivity reaction—Methotrexate—muscle cancer	0.000325	0.00388	CcSEcCtD
Lovastatin—CYP2D6—testis—muscle cancer	0.000325	0.00543	CbGeAlD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.000324	0.0188	CbGpPWpGaD
Lovastatin—Anorexia—Etoposide—muscle cancer	0.000322	0.00385	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000321	0.00384	CcSEcCtD
Lovastatin—Diarrhoea—Dactinomycin—muscle cancer	0.000319	0.00382	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000315	0.00376	CcSEcCtD
Lovastatin—HMGCR—PPARA activates gene expression—MED12—muscle cancer	0.000314	0.0182	CbGpPWpGaD
Lovastatin—Influenza—Doxorubicin—muscle cancer	0.000308	0.00368	CcSEcCtD
Lovastatin—Hypersensitivity—Vincristine—muscle cancer	0.000307	0.00367	CcSEcCtD
Lovastatin—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000307	0.0178	CbGpPWpGaD
Lovastatin—Eosinophilia—Doxorubicin—muscle cancer	0.000305	0.00365	CcSEcCtD
Lovastatin—Paraesthesia—Etoposide—muscle cancer	0.000303	0.00363	CcSEcCtD
Lovastatin—Pancreatitis—Doxorubicin—muscle cancer	0.000302	0.00361	CcSEcCtD
Lovastatin—Dyspnoea—Etoposide—muscle cancer	0.000301	0.0036	CcSEcCtD
Lovastatin—Asthenia—Vincristine—muscle cancer	0.000299	0.00358	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—PMS2—muscle cancer	0.000298	0.0173	CbGpPWpGaD
Lovastatin—Vomiting—Dactinomycin—muscle cancer	0.000297	0.00355	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—ANGPT2—muscle cancer	0.000295	0.0171	CbGpPWpGaD
Lovastatin—Rash—Dactinomycin—muscle cancer	0.000294	0.00352	CcSEcCtD
Lovastatin—Decreased appetite—Etoposide—muscle cancer	0.000294	0.00351	CcSEcCtD
Lovastatin—Fatigue—Etoposide—muscle cancer	0.000291	0.00348	CcSEcCtD
Lovastatin—Constipation—Etoposide—muscle cancer	0.000289	0.00345	CcSEcCtD
Lovastatin—Pain—Etoposide—muscle cancer	0.000289	0.00345	CcSEcCtD
Lovastatin—Diarrhoea—Vincristine—muscle cancer	0.000285	0.00341	CcSEcCtD
Lovastatin—Hepatitis—Methotrexate—muscle cancer	0.000285	0.00341	CcSEcCtD
Lovastatin—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000281	0.00336	CcSEcCtD
Lovastatin—Feeling abnormal—Etoposide—muscle cancer	0.000278	0.00333	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—TP73—muscle cancer	0.000277	0.0161	CbGpPWpGaD
Lovastatin—Nausea—Dactinomycin—muscle cancer	0.000277	0.00332	CcSEcCtD
Lovastatin—Gastrointestinal pain—Etoposide—muscle cancer	0.000276	0.0033	CcSEcCtD
Lovastatin—Dizziness—Vincristine—muscle cancer	0.000276	0.0033	CcSEcCtD
Lovastatin—ABCB1—bone marrow—muscle cancer	0.000273	0.00457	CbGeAlD
Lovastatin—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000272	0.00326	CcSEcCtD
Lovastatin—Erythema multiforme—Methotrexate—muscle cancer	0.000269	0.00322	CcSEcCtD
Lovastatin—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000269	0.00322	CcSEcCtD
Lovastatin—Urticaria—Etoposide—muscle cancer	0.000268	0.00321	CcSEcCtD
Lovastatin—Abdominal pain—Etoposide—muscle cancer	0.000267	0.00319	CcSEcCtD
Lovastatin—Body temperature increased—Etoposide—muscle cancer	0.000267	0.00319	CcSEcCtD
Lovastatin—Urinary tract infection—Doxorubicin—muscle cancer	0.000267	0.00319	CcSEcCtD
Lovastatin—Vomiting—Vincristine—muscle cancer	0.000265	0.00317	CcSEcCtD
Lovastatin—Rash—Vincristine—muscle cancer	0.000263	0.00314	CcSEcCtD
Lovastatin—Dermatitis—Vincristine—muscle cancer	0.000263	0.00314	CcSEcCtD
Lovastatin—ABCB1—vagina—muscle cancer	0.000262	0.00438	CbGeAlD
Lovastatin—Headache—Vincristine—muscle cancer	0.000261	0.00312	CcSEcCtD
Lovastatin—UGT1A1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00026	0.0151	CbGpPWpGaD
Lovastatin—Sinusitis—Doxorubicin—muscle cancer	0.000258	0.00308	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—KIDINS220—muscle cancer	0.000256	0.0149	CbGpPWpGaD
Lovastatin—Chills—Methotrexate—muscle cancer	0.000256	0.00306	CcSEcCtD
Lovastatin—ABCC2—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000254	0.0148	CbGpPWpGaD
Lovastatin—Alopecia—Methotrexate—muscle cancer	0.000252	0.00301	CcSEcCtD
Lovastatin—Hypersensitivity—Etoposide—muscle cancer	0.000249	0.00298	CcSEcCtD
Lovastatin—Nausea—Vincristine—muscle cancer	0.000248	0.00296	CcSEcCtD
Lovastatin—Hepatitis—Doxorubicin—muscle cancer	0.000247	0.00295	CcSEcCtD
Lovastatin—Dysgeusia—Methotrexate—muscle cancer	0.000243	0.0029	CcSEcCtD
Lovastatin—Asthenia—Etoposide—muscle cancer	0.000242	0.0029	CcSEcCtD
Lovastatin—ABCB1—head—muscle cancer	0.000242	0.00404	CbGeAlD
Lovastatin—Back pain—Methotrexate—muscle cancer	0.00024	0.00287	CcSEcCtD
Lovastatin—Pruritus—Etoposide—muscle cancer	0.000239	0.00286	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—TP63—muscle cancer	0.000239	0.0138	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	0.000238	0.0138	CbGpPWpGaD
Lovastatin—Vision blurred—Methotrexate—muscle cancer	0.000234	0.00279	CcSEcCtD
Lovastatin—ABCB1—testis—muscle cancer	0.000233	0.00391	CbGeAlD
Lovastatin—Erythema multiforme—Doxorubicin—muscle cancer	0.000233	0.00279	CcSEcCtD
Lovastatin—Diarrhoea—Etoposide—muscle cancer	0.000231	0.00276	CcSEcCtD
Lovastatin—Ill-defined disorder—Methotrexate—muscle cancer	0.00023	0.00275	CcSEcCtD
Lovastatin—Flushing—Doxorubicin—muscle cancer	0.000229	0.00274	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—CD34—muscle cancer	0.000228	0.0132	CbGpPWpGaD
Lovastatin—Malaise—Methotrexate—muscle cancer	0.000224	0.00267	CcSEcCtD
Lovastatin—Dizziness—Etoposide—muscle cancer	0.000223	0.00267	CcSEcCtD
Lovastatin—Vertigo—Methotrexate—muscle cancer	0.000223	0.00266	CcSEcCtD
Lovastatin—Leukopenia—Methotrexate—muscle cancer	0.000222	0.00265	CcSEcCtD
Lovastatin—Chills—Doxorubicin—muscle cancer	0.000221	0.00265	CcSEcCtD
Lovastatin—Alopecia—Doxorubicin—muscle cancer	0.000218	0.00261	CcSEcCtD
Lovastatin—Vomiting—Etoposide—muscle cancer	0.000215	0.00257	CcSEcCtD
Lovastatin—Rash—Etoposide—muscle cancer	0.000213	0.00255	CcSEcCtD
Lovastatin—Dermatitis—Etoposide—muscle cancer	0.000213	0.00254	CcSEcCtD
Lovastatin—Headache—Etoposide—muscle cancer	0.000212	0.00253	CcSEcCtD
Lovastatin—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000212	0.0123	CbGpPWpGaD
Lovastatin—Flatulence—Doxorubicin—muscle cancer	0.000212	0.00253	CcSEcCtD
Lovastatin—Chest pain—Methotrexate—muscle cancer	0.000211	0.00252	CcSEcCtD
Lovastatin—Myalgia—Methotrexate—muscle cancer	0.000211	0.00252	CcSEcCtD
Lovastatin—Arthralgia—Methotrexate—muscle cancer	0.000211	0.00252	CcSEcCtD
Lovastatin—Dysgeusia—Doxorubicin—muscle cancer	0.00021	0.00251	CcSEcCtD
Lovastatin—Discomfort—Methotrexate—muscle cancer	0.000209	0.00249	CcSEcCtD
Lovastatin—Back pain—Doxorubicin—muscle cancer	0.000208	0.00248	CcSEcCtD
Lovastatin—Muscle spasms—Doxorubicin—muscle cancer	0.000206	0.00247	CcSEcCtD
Lovastatin—Confusional state—Methotrexate—muscle cancer	0.000204	0.00244	CcSEcCtD
Lovastatin—Anaphylactic shock—Methotrexate—muscle cancer	0.000202	0.00242	CcSEcCtD
Lovastatin—Vision blurred—Doxorubicin—muscle cancer	0.000202	0.00242	CcSEcCtD
Lovastatin—Infection—Methotrexate—muscle cancer	0.000201	0.0024	CcSEcCtD
Lovastatin—Nausea—Etoposide—muscle cancer	0.000201	0.0024	CcSEcCtD
Lovastatin—Ill-defined disorder—Doxorubicin—muscle cancer	0.000199	0.00238	CcSEcCtD
Lovastatin—Thrombocytopenia—Methotrexate—muscle cancer	0.000198	0.00237	CcSEcCtD
Lovastatin—HDAC2—Cell Cycle—BUB1B—muscle cancer	0.000198	0.0115	CbGpPWpGaD
Lovastatin—Malaise—Doxorubicin—muscle cancer	0.000194	0.00232	CcSEcCtD
Lovastatin—Vertigo—Doxorubicin—muscle cancer	0.000193	0.00231	CcSEcCtD
Lovastatin—Anorexia—Methotrexate—muscle cancer	0.000193	0.00231	CcSEcCtD
Lovastatin—Leukopenia—Doxorubicin—muscle cancer	0.000192	0.0023	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000184	0.0022	CcSEcCtD
Lovastatin—Insomnia—Methotrexate—muscle cancer	0.000183	0.00219	CcSEcCtD
Lovastatin—Myalgia—Doxorubicin—muscle cancer	0.000183	0.00219	CcSEcCtD
Lovastatin—Chest pain—Doxorubicin—muscle cancer	0.000183	0.00219	CcSEcCtD
Lovastatin—Arthralgia—Doxorubicin—muscle cancer	0.000183	0.00219	CcSEcCtD
Lovastatin—Anxiety—Doxorubicin—muscle cancer	0.000182	0.00218	CcSEcCtD
Lovastatin—Paraesthesia—Methotrexate—muscle cancer	0.000182	0.00217	CcSEcCtD
Lovastatin—Discomfort—Doxorubicin—muscle cancer	0.000181	0.00216	CcSEcCtD
Lovastatin—Dyspnoea—Methotrexate—muscle cancer	0.00018	0.00216	CcSEcCtD
Lovastatin—Dry mouth—Doxorubicin—muscle cancer	0.000179	0.00214	CcSEcCtD
Lovastatin—Dyspepsia—Methotrexate—muscle cancer	0.000178	0.00213	CcSEcCtD
Lovastatin—Confusional state—Doxorubicin—muscle cancer	0.000177	0.00211	CcSEcCtD
Lovastatin—Decreased appetite—Methotrexate—muscle cancer	0.000176	0.0021	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	0.000176	0.0102	CbGpPWpGaD
Lovastatin—Anaphylactic shock—Doxorubicin—muscle cancer	0.000175	0.0021	CcSEcCtD
Lovastatin—Fatigue—Methotrexate—muscle cancer	0.000174	0.00209	CcSEcCtD
Lovastatin—Infection—Doxorubicin—muscle cancer	0.000174	0.00208	CcSEcCtD
Lovastatin—Pain—Methotrexate—muscle cancer	0.000173	0.00207	CcSEcCtD
Lovastatin—Thrombocytopenia—Doxorubicin—muscle cancer	0.000172	0.00205	CcSEcCtD
Lovastatin—Anorexia—Doxorubicin—muscle cancer	0.000167	0.002	CcSEcCtD
Lovastatin—Feeling abnormal—Methotrexate—muscle cancer	0.000167	0.00199	CcSEcCtD
Lovastatin—Gastrointestinal pain—Methotrexate—muscle cancer	0.000165	0.00198	CcSEcCtD
Lovastatin—Urticaria—Methotrexate—muscle cancer	0.000161	0.00192	CcSEcCtD
Lovastatin—Abdominal pain—Methotrexate—muscle cancer	0.00016	0.00191	CcSEcCtD
Lovastatin—Body temperature increased—Methotrexate—muscle cancer	0.00016	0.00191	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00016	0.00191	CcSEcCtD
Lovastatin—Insomnia—Doxorubicin—muscle cancer	0.000158	0.0019	CcSEcCtD
Lovastatin—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000158	0.00919	CbGpPWpGaD
Lovastatin—Paraesthesia—Doxorubicin—muscle cancer	0.000157	0.00188	CcSEcCtD
Lovastatin—Dyspnoea—Doxorubicin—muscle cancer	0.000156	0.00187	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—FOXO4—muscle cancer	0.000155	0.00898	CbGpPWpGaD
Lovastatin—Dyspepsia—Doxorubicin—muscle cancer	0.000154	0.00184	CcSEcCtD
Lovastatin—Decreased appetite—Doxorubicin—muscle cancer	0.000152	0.00182	CcSEcCtD
Lovastatin—Fatigue—Doxorubicin—muscle cancer	0.000151	0.00181	CcSEcCtD
Lovastatin—Constipation—Doxorubicin—muscle cancer	0.00015	0.00179	CcSEcCtD
Lovastatin—Pain—Doxorubicin—muscle cancer	0.00015	0.00179	CcSEcCtD
Lovastatin—Hypersensitivity—Methotrexate—muscle cancer	0.000149	0.00178	CcSEcCtD
Lovastatin—Asthenia—Methotrexate—muscle cancer	0.000145	0.00174	CcSEcCtD
Lovastatin—Feeling abnormal—Doxorubicin—muscle cancer	0.000144	0.00173	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—IGF2—muscle cancer	0.000144	0.00833	CbGpPWpGaD
Lovastatin—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000143	0.00171	CcSEcCtD
Lovastatin—Pruritus—Methotrexate—muscle cancer	0.000143	0.00171	CcSEcCtD
Lovastatin—Urticaria—Doxorubicin—muscle cancer	0.000139	0.00166	CcSEcCtD
Lovastatin—Abdominal pain—Doxorubicin—muscle cancer	0.000139	0.00166	CcSEcCtD
Lovastatin—Body temperature increased—Doxorubicin—muscle cancer	0.000139	0.00166	CcSEcCtD
Lovastatin—Diarrhoea—Methotrexate—muscle cancer	0.000138	0.00166	CcSEcCtD
Lovastatin—ITGAL—Immune System—CD34—muscle cancer	0.000138	0.00801	CbGpPWpGaD
Lovastatin—Dizziness—Methotrexate—muscle cancer	0.000134	0.0016	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000134	0.00776	CbGpPWpGaD
Lovastatin—CYP2C19—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000132	0.00769	CbGpPWpGaD
Lovastatin—ITGAL—Focal Adhesion—VEGFA—muscle cancer	0.000132	0.00765	CbGpPWpGaD
Lovastatin—Hypersensitivity—Doxorubicin—muscle cancer	0.000129	0.00154	CcSEcCtD
Lovastatin—Vomiting—Methotrexate—muscle cancer	0.000129	0.00154	CcSEcCtD
Lovastatin—Rash—Methotrexate—muscle cancer	0.000128	0.00153	CcSEcCtD
Lovastatin—Dermatitis—Methotrexate—muscle cancer	0.000127	0.00152	CcSEcCtD
Lovastatin—Headache—Methotrexate—muscle cancer	0.000127	0.00152	CcSEcCtD
Lovastatin—Asthenia—Doxorubicin—muscle cancer	0.000126	0.0015	CcSEcCtD
Lovastatin—Pruritus—Doxorubicin—muscle cancer	0.000124	0.00148	CcSEcCtD
Lovastatin—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000122	0.00711	CbGpPWpGaD
Lovastatin—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000122	0.00707	CbGpPWpGaD
Lovastatin—Nausea—Methotrexate—muscle cancer	0.00012	0.00144	CcSEcCtD
Lovastatin—Diarrhoea—Doxorubicin—muscle cancer	0.00012	0.00143	CcSEcCtD
Lovastatin—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000119	0.00694	CbGpPWpGaD
Lovastatin—Dizziness—Doxorubicin—muscle cancer	0.000116	0.00139	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—FOXO1—muscle cancer	0.000114	0.00663	CbGpPWpGaD
Lovastatin—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000112	0.00648	CbGpPWpGaD
Lovastatin—Vomiting—Doxorubicin—muscle cancer	0.000111	0.00133	CcSEcCtD
Lovastatin—Rash—Doxorubicin—muscle cancer	0.00011	0.00132	CcSEcCtD
Lovastatin—Dermatitis—Doxorubicin—muscle cancer	0.00011	0.00132	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	0.00011	0.00638	CbGpPWpGaD
Lovastatin—Headache—Doxorubicin—muscle cancer	0.00011	0.00131	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.000104	0.00607	CbGpPWpGaD
Lovastatin—Nausea—Doxorubicin—muscle cancer	0.000104	0.00124	CcSEcCtD
Lovastatin—ITGAL—Immune System—FOXO4—muscle cancer	9.38e-05	0.00545	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—ANGPT2—muscle cancer	9.08e-05	0.00527	CbGpPWpGaD
Lovastatin—HDAC2—Cell Cycle—CDKN2A—muscle cancer	9.05e-05	0.00525	CbGpPWpGaD
Lovastatin—HDAC2—Cell Cycle—MDM2—muscle cancer	8.78e-05	0.00509	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—KIT—muscle cancer	8.7e-05	0.00505	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—FOXO4—muscle cancer	8.68e-05	0.00504	CbGpPWpGaD
Lovastatin—HMGCR—AMPK Signaling—TP53—muscle cancer	8.61e-05	0.005	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.42e-05	0.00489	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	8.02e-05	0.00466	CbGpPWpGaD
Lovastatin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	7.36e-05	0.00427	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—FOXO1—muscle cancer	6.93e-05	0.00402	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—MDM2—muscle cancer	6.85e-05	0.00398	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—MDM2—muscle cancer	6.81e-05	0.00395	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—FH—muscle cancer	6.64e-05	0.00386	CbGpPWpGaD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	6.47e-05	0.00376	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—FOXO1—muscle cancer	6.41e-05	0.00372	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	6.09e-05	0.00354	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—VEGFA—muscle cancer	6.02e-05	0.0035	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—TP53—muscle cancer	6e-05	0.00348	CbGpPWpGaD
Lovastatin—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	5.55e-05	0.00322	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KIDINS220—muscle cancer	5.51e-05	0.0032	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—FH—muscle cancer	5.41e-05	0.00314	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	5.3e-05	0.00308	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—KIT—muscle cancer	5.28e-05	0.00306	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.09e-05	0.00295	CbGpPWpGaD
Lovastatin—HDAC2—Cell Cycle—TP53—muscle cancer	5.04e-05	0.00292	CbGpPWpGaD
Lovastatin—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	4.96e-05	0.00288	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—KIT—muscle cancer	4.88e-05	0.00284	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NOTCH—TP53—muscle cancer	4.77e-05	0.00277	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—FH—muscle cancer	4.6e-05	0.00267	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—muscle cancer	4.6e-05	0.00267	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—TP53—muscle cancer	4.55e-05	0.00264	CbGpPWpGaD
Lovastatin—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	4.52e-05	0.00262	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—IGF2—muscle cancer	4.41e-05	0.00256	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.35e-05	0.00252	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—MDM2—muscle cancer	4.16e-05	0.00241	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—FH—muscle cancer	4.01e-05	0.00233	CbGpPWpGaD
Lovastatin—HDAC2—Factors involved in megakaryocyte development and platelet production—TP53—muscle cancer	4e-05	0.00232	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—TP53—muscle cancer	3.91e-05	0.00227	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.87e-05	0.00225	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—MED12—muscle cancer	3.86e-05	0.00224	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—MDM2—muscle cancer	3.85e-05	0.00223	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—MED12—muscle cancer	3.75e-05	0.00218	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—FH—muscle cancer	3.74e-05	0.00217	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—FH—muscle cancer	3.43e-05	0.00199	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—ENO2—muscle cancer	3.42e-05	0.00199	CbGpPWpGaD
Lovastatin—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	3.3e-05	0.00192	CbGpPWpGaD
Lovastatin—HDAC2—Disease—ENO2—muscle cancer	3.27e-05	0.0019	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—FH—muscle cancer	3.15e-05	0.00183	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—MED12—muscle cancer	3.06e-05	0.00178	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	3.05e-05	0.00177	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HMGA1—muscle cancer	2.97e-05	0.00172	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—TP53—muscle cancer	2.93e-05	0.0017	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—ENO2—muscle cancer	2.79e-05	0.00162	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.68e-05	0.00155	CbGpPWpGaD
Lovastatin—HDAC2—Disease—FOXO4—muscle cancer	2.66e-05	0.00155	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—VEGFA—muscle cancer	2.64e-05	0.00153	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—MED12—muscle cancer	2.6e-05	0.00151	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.5e-05	0.00145	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—ENO2—muscle cancer	2.37e-05	0.00138	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—FH—muscle cancer	2.27e-05	0.00132	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—MED12—muscle cancer	2.26e-05	0.00131	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.23e-05	0.00129	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PTCH1—muscle cancer	2.17e-05	0.00126	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—MED12—muscle cancer	2.11e-05	0.00123	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—ENO2—muscle cancer	2.06e-05	0.0012	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.03e-05	0.00118	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—FH—muscle cancer	1.97e-05	0.00114	CbGpPWpGaD
Lovastatin—HDAC2—Disease—FOXO1—muscle cancer	1.97e-05	0.00114	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—MED12—muscle cancer	1.94e-05	0.00112	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—ENO2—muscle cancer	1.93e-05	0.00112	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—FOXO4—muscle cancer	1.86e-05	0.00108	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—VEGFA—muscle cancer	1.85e-05	0.00107	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CNR1—muscle cancer	1.83e-05	0.00106	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—MED12—muscle cancer	1.78e-05	0.00103	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—ENO2—muscle cancer	1.77e-05	0.00103	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—FH—muscle cancer	1.76e-05	0.00102	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.72e-05	0.000997	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—FH—muscle cancer	1.72e-05	0.000996	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.66e-05	0.000961	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—ENO2—muscle cancer	1.62e-05	0.000941	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—FH—muscle cancer	1.62e-05	0.000939	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.61e-05	0.000937	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—FH—muscle cancer	1.6e-05	0.000931	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KIT—muscle cancer	1.5e-05	0.00087	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IGF2—muscle cancer	1.5e-05	0.000869	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TP53—muscle cancer	1.4e-05	0.000812	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.38e-05	0.000802	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—FOXO1—muscle cancer	1.38e-05	0.000799	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.3e-05	0.000757	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—MED12—muscle cancer	1.28e-05	0.000746	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTGS2—muscle cancer	1.19e-05	0.000692	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MDM2—muscle cancer	1.18e-05	0.000685	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—ENO2—muscle cancer	1.17e-05	0.00068	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTGS2—muscle cancer	1.14e-05	0.00066	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—MED12—muscle cancer	1.11e-05	0.000646	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—FH—muscle cancer	1.06e-05	0.000614	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KIT—muscle cancer	1.05e-05	0.000609	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—ENO2—muscle cancer	1.01e-05	0.000589	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—MED12—muscle cancer	9.93e-06	0.000577	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	9.85e-06	0.000572	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTGS2—muscle cancer	9.71e-06	0.000564	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—MED12—muscle cancer	9.69e-06	0.000563	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—MED12—muscle cancer	9.14e-06	0.00053	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—MED12—muscle cancer	9.06e-06	0.000526	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—ENO2—muscle cancer	9.06e-06	0.000526	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—ENO2—muscle cancer	8.84e-06	0.000513	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—ENO2—muscle cancer	8.33e-06	0.000484	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MDM2—muscle cancer	8.26e-06	0.00048	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTGS2—muscle cancer	8.26e-06	0.000479	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—ENO2—muscle cancer	8.26e-06	0.000479	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.93e-06	0.000461	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTGS2—muscle cancer	7.19e-06	0.000418	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.08e-06	0.000411	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTGS2—muscle cancer	6.71e-06	0.00039	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.46e-06	0.000375	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—VEGFA—muscle cancer	6.27e-06	0.000364	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTGS2—muscle cancer	6.15e-06	0.000357	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—MED12—muscle cancer	5.97e-06	0.000347	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTGS2—muscle cancer	5.64e-06	0.000328	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—ENO2—muscle cancer	5.45e-06	0.000316	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—muscle cancer	4.74e-06	0.000275	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTGS2—muscle cancer	4.08e-06	0.000237	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTGS2—muscle cancer	3.53e-06	0.000205	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTGS2—muscle cancer	3.15e-06	0.000183	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTGS2—muscle cancer	3.08e-06	0.000179	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTGS2—muscle cancer	2.9e-06	0.000168	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTGS2—muscle cancer	2.88e-06	0.000167	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTGS2—muscle cancer	1.9e-06	0.00011	CbGpPWpGaD
